From Osaka to the world: How OCCI’s DSANJ gives med-biotech startups a “right-path” roadmap
Osaka–Kansai concentrates world-class science, hospitals, and deep manufacturing craft. For ~25 years, the Osaka Chamber of Commerce and Industry (OCCI) has acted as a hands-on orchestrator connecting academia, clinicians, and industry beyond the Kansai region.
At the core sits the Drug Seeds Alliance Network Japan (#DSANJ)—a native database and online matching program launched in 2010 and co-organized with #AMED and #JPMA. Across twice-yearly DSANJ Bio Conferences, ~40 pharma/VC evaluate uploaded proposals and hold 1:1 meetings with researchers and startups from Japan and abroad, including teams from Taiwan. OCCI’s expert panel “translates” science into industry-ready language, while a parallel medtech track aggregates real unmet clinical needs from hospitals and feeds them back to makers.
Beyond matching, OCCI is codifying market sequencing—e.g., Melbourne clinicals → Japan regulatory build-out → U.S. market validation—via an MoU with MedTech Actuator linking Osaka, Singapore, and Melbourne. Capital and talent underpin the flywheel: small-cohort founder trainings with clinicians and device leaders, plus new bridges to overseas investors.
Why it matters: Fewer detours, faster proof, better fit-for-market roadmaps. If you’re a founder, clinician-innovator, or investor building in TechBio/Medtech, Osaka is becoming a hub that standardizes evidence, de-risks adoption, and accelerates scale.
Read the full interview articles here:
– EN: https://bit.ly/4pWRh0W
– CH: https://bit.ly/4qhf6AX
